

Fastställelseintyg till årsredovisning

Financial Statements Approval

Intyg om att balansräkningen och resultaträkningen har fastställts

Certification that the balance sheet and income statement have been adopted

Undertecknad styrelseledamot i Recipharm Karlskoga Fastighets Aktiebolag, org.nr 556657-8315, intygar, dels att denna kopia av årsredovisningen stämmer överens med originalet, dels att resultaträkningen och balansräkningen har fastställts på årsstämman den 14 juni 2024. Årsstämman beslutade att godkänna styrelsens förslag till hur resultatet ska disponeras.

The undersigned board member of Recipharm Karlskoga Fastighets Aktiebolag, reg. no. 556657-8315, hereby certifies that this copy of the annual report conforms to the original and that the income statement and balance sheet were adopted on 14 June 2024. The annual general meeting resolved to adopt the board's proposal regarding the allocation of the company's profits.

Stockholm den

25/6-24

Stockholm, _____


Jörgen Rahm

ank=20240628;2024070105345

ÅRSREDOVISNING

för

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2023-01-01 - 2023-12-31

Innehåll	Sida
- förvaltningsberättelse	2
- resultaträkning	4
- balansräkning	5
- noter	7
- underskrifter	8

I hereby certify that this is a true copy
of the original.

Roschier Advokatbyrå AB
P.O. Box 7358
SE-103 90 Stockholm, Sweden

Kimia Vafadar Esfahani
Kimia Vafadar
26 June 2024

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

FÖRVALTNINGSBERÄTTELSE

Årsredovisningen är upprättad i svenska kronor, SEK.

Verksamheten**Allmänt om verksamheten**

Fastigheten Karlskoga Bofors 1:10 i Karlskoga kommun.

Recipharm Karlskoga Fastighets AB's verksamhet består av att äga och förvalta en fastighet. Företaget hyr ut fastigheten till ett av systerföretagen i koncernen, Recipharm Karlskoga AB och lokalen skall användas för läkemedelsindustri. Företaget har inte haft anställd personal under innevarande räkenskapsår.

Bolagets likvida medel är placerad i koncernens gemensamma cash pool som redovisas som fordran eller skuld mot moderbolaget. Verksamheten i övrigt finansieras genom upplåning från moderbolaget.

Recipharm Karlskoga Fastighets AB har sitt säte i Stockholm.

From räkenskapsåret 2022 bolaget har valt att inte ha revisor.

Väsentliga händelser under räkenskapsåret

Inga väsentliga händelser som har inträffat under räkenskapsåret.

Flerårsöversikt

Beloppen i Flerårsöversikt visas i SEK

	2023	2022	2021	2020
Nettoomsättning	439 987	382 701	370 668	371 887
Resultat efter finansiella poster	370 016	294 601	263 620	283 296
Soliditet (%)	33,29	30,13	32,00	28,29
Resultat i % av nettoomsättningen	84,09	76,97	71,12	76,17
Balansomslutning	564 964	562 440	528 047	597 371

Definitioner av nyckeltal

Definitioner av nyckeltal.

Soliditet= eget kapital i relation till balansomslutningen.

Resultat i % av nettoomsättning= resultat efter finansiella poster i relation till nettoomsättningen.

Förändringar i eget kapital

	Aktiekapital	Balanserat resultat	Årets resultat	Summa eget kapital
Belopp vid årets ingång	100 000	69 005	491	169 496
Balanseras i ny räkning		491	-491	0
Årets resultat			18 625	18 625
Belopp vid årets utgång	100 000	69 496	18 625	188 121

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

Resultatdisposition

Styrelsens förslag till disposition av bolagets vinst

Balanserat resultat	69 496
Årets resultat	<u>18 625</u>
	88 121
Förslag till disposition:	
Balanseras i ny räkning	<u>88 121</u>
	88 121

Beträffande bolagets resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

ark=20240628;2024070103346

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

RESULTATRÄKNING

	Not	2023-01-01 2023-12-31	2022-01-01 2022-12-31
Rörelseintäkter m.m.			
Nettoomsättning	2	439 987	382 701
Summa rörelseintäkte m.m.		439 987	382 701
Rörelsekostnader			
Övriga externa kostnader		-72 540	-72 535
Avskrivningar av materiella anläggningstillgångar		-16 056	-16 056
Summa rörelsekostnader		-88 596	-88 591
Rörelseresultat		351 391	294 110
Finansiella poster			
Övriga ränteintäkter och liknande resultatposter		18 625	491
Summa finansiella poster		18 625	491
Resultat efter finansiella poster		370 016	294 601
Bokslutsdispositioner			
Lämnade koncernbidrag		-351 391	-294 110
Summa bokslutsdispositioner		-351 391	-294 110
Resultat före skatt		18 625	491
Årets resultat		18 625	491

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

BALANSRÄKNING

	2023-12-31	2022-12-31
--	------------	------------

EGET KAPITAL OCH SKULDER**Eget kapital****Bundet eget kapital**

Aktiekapital

100 000

100 000

Summa bundet eget kapital

100 000

100 000

Fritt eget kapital

Balanserat resultat

69 496

69 005

Årets resultat

18 625

491

Summa fritt eget kapital

88 121

69 496

Summa eget kapital

188 121

169 496

Kortfristiga skulder

Skulder till koncernföretag

351 391

294 110

Skatteskulder

0

72 535

Övriga skulder

25 452

26 299

Summa kortfristiga skulder

376 843

392 944

SUMMA EGET KAPITAL OCH SKULDER**564 964****562 440**

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

NOTER**Not 1 Redovisnings- och värderingsprinciper**

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag (K2)

Värderingsprinciper m.m.

Tillgångar, avsättningar och skulder har värderats till anskaffningsvärden om inget annat anges nedan.

Fordringar

Fordringar har upptagits till de belopp varmed de beräknas inflyta.

Koncernbidrag

Koncernbidrag redovisas i enlighet med BFNAR 2016:10 Årsredovisning i mindre aktiebolag som bokslutsdisponition.

Nettoomsättning avser summan av årets hyresintäkter.

Materiella anläggningstillgångar**Tillämpade avskrivningstider:****Antal år**

Byggnader

25

Materiella anläggningstillgångar redovisas till anskaffningsvärde med avdrag för ackumulerad värdeminskning och eventuella nedskrivning. Tillgångarna skrivs av linjärt över tillgångarnas nyttjandeperiod.

Not 2	Inköp och försäljning mellan koncernföretag	2023	2022
	Årets inköp från koncernföretag i %	0%	0%
	Årets försäljning till koncernföretag i %	100%	100%

Not 3	Byggnader och mark	2023-12-31	2022-12-31
	Ingående anskaffningsvärden	<u>535 270</u>	<u>535 270</u>
	Utgående anskaffningsvärden	535 270	535 270
	Ingående avskrivningar	-292 993	-276 937
	Årets avskrivningar	<u>-16 056</u>	<u>-16 056</u>
	Utgående avskrivningar	-309 049	-292 993
	Redovisat värde	<u>226 221</u>	<u>242 277</u>

Taxeringsvärden

Mark	3 442 000	3 442 000
Byggnader	11 065 000	11 065 000

Avskrivningar enligt plan beräknas på en nyttjandeperiod av 25 år.

Recipharm Karlskoga Fastighets AB

Org.nr. 556657-8315

NOTER**Not 4 Väsentliga händelser efter räkenskapsårets slut**

I mars 2024 såldes bolaget tillsammans med andra bolag från Recipharm koncernen till ett amerikanskt riskkapitalbolag. Den nya företagsgruppen kommer fortsätta verka i CDMO branschen under ett ännu ej publicerat namn, men moderbolaget är Magic Dose TopCo AB (559456-1473), med säte i Stockholm. Transaktionen förväntas avslutas under 2024. Ägarförändringen förväntas inte direkt påverka bolagets resultat och ställning.

Not 5 Ställda säkerheter	2023-12-31	2022-12-31
Fastighetsinteckningar	15 000 000	15 000 000
Summa ställda säkerheter	15 000 000	15 000 000


Not 6 Eventualförpliktelser


Bolaget har inga eventualförpliktelser.

Not 7 Koncernförhållanden

Bolaget är helägt dotterbolag till Recipharm AB, Orgnr 556498-8425, med säte i Stockholm. Övergripande koncernredovisning upprättas av Roar HoldCo, 559283-6950, med säte i Stockholm.

Datum framgår av den elektroniska signaturen

DocuSigned by:

D733996FF51D4FA...
Jörgen Rahm
Styrelseledamot

DocuSigned by:

BA90B6B8714A4C7...
Ingela Marie Palmkvist
Styrelseledamot

Certificate Of Completion

Envelope Id: 4217E56F6AFD4AF18F1514ABC93B3CFD
Subject: Signing of 2023 Swedish Annual Accounts for RKF
Source Envelope: 867D9ECA317C40979E622764B1F73E60
Document Pages: 8
Certificate Pages: 4
AutoNav: Enabled
Envelopeld Stamping: Enabled
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna

Status: Completed
Envelope Originator:
Jorgen.rahm
Drottninggatan 29
Stockholm, Stockholm 111 51
Jorgen.rahm@recipharm.com
IP Address: 81.233.72.205

Record Tracking


Status: Original
Holder: Jorgen.rahm
5/17/2024 8:41:40 AM
Jorgen.rahm@recipharm.com

Location: DocuSign

Signer Events

Ingela Palmqvist
ingela.palmkvist@recipharm.com
Site Manager
Security Level: Email, Account Authentication (None)

Signature



Signature Adoption: Pre-selected Style
Using IP Address: 80.76.144.70

Timestamp

Sent: 5/17/2024 8:45:47 AM
Viewed: 5/17/2024 8:46:51 AM
Signed: 5/17/2024 8:48:33 AM
Freeform Signing

Electronic Record and Signature Disclosure:

Accepted: 5/17/2024 8:46:51 AM
ID: d8a6e592-c5bd-4de3-b205-1eb2583848f3

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent Hashed/Encrypted 5/17/2024 8:45:47 AM
Certified Delivered Security Checked 5/17/2024 8:46:51 AM
Signing Complete Security Checked 5/17/2024 8:48:33 AM
Completed Security Checked 5/17/2024 8:48:33 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

ank=20240628;2024070103349

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Recipharm AB (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Recipharm AB:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: robert.siden@recipharm.com

To advise Recipharm AB of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at robert.siden@recipharm.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Recipharm AB

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to robert.siden@recipharm.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Recipharm AB

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to robert.siden@recipharm.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Recipharm AB as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Recipharm AB during the course of your relationship with Recipharm AB.